The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
08-Dec-21
$240 million
Target:
Alert 360
Acquiror:
My Alarm Center
Advising My Alarm Center, a nationwide provider of security and smart home monitoring services, on the acquisition of Alert 360, a leading competitor in the alarm monitoring industry
07-Dec-21
Pending
$153 million
Target:
Japan Medical Dynamic Marketing
Acquiror:
Mitsui Chemicals
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
10-Nov-21
Undisclosed
Target:
Bell's Brewery
Acquiror:
Lion / Kirin
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
20-Sep-21
Undisclosed
Target:
Faes Farma, flagship product Bilastine
Acquiror:
Hikma Specialty USA INC
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
11-Sep-21
Pending
Undisclosed
Target:
California-based Property and Casualty insurance subsidiary of Covéa
Acquiror:
Porch Group
Advising Covéa, a leading French mutual insurance company, on the sale of its wholly owned subsidiary, CSE Insurance group, to Porch Group
09-Sep-21
Undisclosed
Target:
Quicken
Acquiror:
Aquiline Capital Partners
Advised Aquiline Capital Partners on its acquisition of Quicken, the best-selling personal finance software in the U.S., from H.I.G. Capital
12-Jul-21
Pending
$1.7 billion
Target:
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
Acquiror:
KPS Capital Partners
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
05-Jul-21
Undisclosed
Target:
American Stock Transfer & Trust Company
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its acquisition of American Stock Transfer & Trust Company, a leading technology-enabled full service professional services firm
30-Jun-21
Pending
Undisclosed
Target:
Deltalab
Acquiror:
SCG Packaging Public Company Limited
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
07-Jun-21
Undisclosed
Target:
Rights to General, Right Guard and Dry Idea brands
Acquiror:
N/A
Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)
03-Jun-21
Undisclosed
Target:
Le Petit Depot
Acquiror:
Phoon Huat
Advised Le Petit Depot, Singapore’s leading online platform specializing in the sale of European food products, on the sale of a controlling stake to, and strategic partnership with, Phoon Huat
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
27-May-21
$1.4 billion
Target:
Equiniti Group PLC
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
10-May-21
Pending
N/A
Target:
International Flavors & Fragrances, Inc.’s Fruit Preparations business
Acquiror:
Frulact Serviços Partilhados, SA
Advised International Flavors & Fragrances on the divestiture of its European-based Fruit Preparation business to Frulact Serviços Partilhados, SA
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
26-Feb-21
Undisclosed
Target:
MDLIVE
Acquiror:
Cigna
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
15-Sep-20
$NA
Target:
Surgery Partners’ Anesthesia Services
Acquiror:
NorthStar Anesthesia
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
12-Aug-20
$225 million
Target:
340B Link
Acquiror:
Omnicell
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$134 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
09-Jun-20
$1.02 billion
Target:
LIXIL VIVA
Acquiror:
Arcland Sakamoto
Advising Arcland Sakamoto, a leading owner and operator of large home centers, on the acquisition of LIXIL VIVA, a leading owner and operator of large home centers and a listed subsidiary of LIXIL Group, a leading Japanese manufacturer of building and housing materials